PUBLIC PORTAL

MEDICALLY REVIEWED

Tepotinib (Tepmetko) for METex14-altered NSCLC

Share on email
Share on print
Share on whatsapp

Tepotinib (Tepmetko) was recently approved for the use of Non-Small Cell Lung Cancer (NSCLC). Find out about the Phase II VISION trial here . . .

Login or Sign Up as a healthcare professional to read the full article.

Share via

Share on email
Share on facebook
Share on whatsapp
Share on telegram
Share on twitter
Share on linkedin

Also worth reading